At the outset of the Covid-19 pandemic a remarkable mobilisation of resources occurred; governments removed anti-trust restrictions and provided capital, pharmaceutical companies large and small collaborated, and biotechnology companies and universities pooled knowledge. There were still regulatory roadblocks and problems of scale, but the significant scientific breakthroughs and miraculous innovations have helped combat the disease. This panel will discuss how (or if) the intellectual property laws of different countries helped the innovation of new diagnostics, treatments and vaccines related to Covid-19. The panel will also discuss whether the intellectual property laws helped, or hindered, the distribution of those same technologies.